Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MaaT013 in pediatric gastrointestinal acute graft-versus-host disease after steroid and ruxolitinib failure
NL-OMON61061Phase 2Not yet recruiting
- Sponsor
- MaaT Pharma
- Start
- May 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MaaT013 in Acute Graft-Versus-Host Disease (aGvHD), sponsored by MaaT Pharma. Primary endpoints: Safety and tolerability through Month 6, Safety from Month 6 to Month 12 and 5 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
MaaT013
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NL-OMON61061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61061.